Brief: Apogee Therapeutics Inc $681.4 Million Cash, Cash Equivalents And Marketable Securities Supports Runway Into Q1 2028
May 12 (Reuters) - Apogee Therapeutics Inc APGE.O: APOGEE THERAPEUTICS INC: $681.4 MILLION CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES SUPPORTS RUNWAY INTO Q1 2028 Source text: ID:nGNXb0Hv2G Further company coverage: APGE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apogee Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Abbvie Seeks At Least $8 Billion In Debt To Fund Apogee Deal - Bloomberg News
Street View: Strength in AbbVie's immunology pipeline to support revenue growth
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates (updated)